Visit DiaCarta Team at Booth 24151 at ASCO Annual Meeting 2023

Transforming Cancer Care with

SPOT ON Precision Diagnostics

Breaking News!

QuantiVirus™ MPXV Test Kit has been granted with FDA EUA for Monkeypox virus detection

Press Release

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

Press Release

DiaCarta to Become a Publicly Listed Company

Through Merger with HH&L Acquisition Co.

Media Coverage by Genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay

to Gauge Chemotherapy Response

in Multiple Cancers

Visit DiaCarta Team at Booth 24151 at ASCO Annual Meeting 2023

Transforming Cancer Care with SPOT ON Precision Diagnostics

Breaking News!

QuantiVirus™ MPXV Test Kit has been granted with FDA EUA for Monkeypox virus detection

Press Release

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

Press Release

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

Media Coverage by genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers

DiaCarta is a leading precision diagnostic company that specializes in providing comprehensive cancer patient management solutions. We offer a range of products and services, including early detection/screening, diagnostics, therapy selection, and recurrence/resistance monitoring. Our XNA technology, enables us to provide solutions with high sensitivity and affordability, making DiaCarta a one-stop-shop for cancer patient management.

Our proprietary XNA technology allows for sensitive, accurate, and cost-effective detection of genetic alterations using different genomic platforms, positioning us as a leader in the precision diagnostic industry. Our suite of diagnostic products and services, including RadTox™, ColoScape™, and Oncura™, along with our range of infectious disease tests, such as HPV tests and MonkeyPox tests, deliver superior clinical performance and economic value to healthcare providers and patients worldwide.

Headquartered in Pleasanton, California, with subsidiaries in Europe and Asia, we operate 37,000 square feet of CAP-accredited CLIA lab and ISO 13485 certified GMP manufacturing facility, innovative R&D lab, and office space in the US. Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.

HPV mRNA Screening

NGS Targeted Sequencing

CLIA Lab Service

ULTRA-SENSITIVE

XNA Technology

XNA, xenonucleic acids, are innovative new nucleic acid molecular oligomers that hybridize by Watson-Crick base pairing to target DNA sequences, and yet have a modified chemical backbone. XNA oligomers are highly effective at hybridizing to targeted normal DNA sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (qPCR) or as highly specific molecular probes for the detection of nucleic acid target sequences. The XNA tightly binds to the wild-type sequence that is 100% complementary and blocks DNA polymerase from DNA elongation; only the mutant target sequence gets amplified because the XNA:mutant DNA duplex is not stable due to mismatch and fall off from the template in PCR reactions.

ULTRA-SENSITIVE

isobDNA™ Technology

isobDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, isobDNA™ technology does not amplify the DNA or RNA in the samples but amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. isobDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases. 

DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta’s leadership and commitment to excellence.

Early Cancer Detection Will Save More Lives

Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...

X